Patent intelligence · US
US 10632072
Systems and methods for continuous manufacturing of liposomal drug formulations
Systems and methods for continuous manufacturing of liposomal drug formulations
Patent details — US 10632072
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 28, 2020
- Expiration
- Apr 23, 2040
- Applicant
- UNIVERSITY OF CONNECTICUT
- Claims
- 19
- CPC classes
- A61K, A61K9/1277
Quick answer
US 10632072 (Systems and methods for continuous manufacturing of liposomal drug formulations) is held by UNIVERSITY OF CONNECTICUT. Status: granted. Granted Apr 28, 2020. Expires Apr 23, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- UNIVERSITY OF CONNECTICUT
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K9/1277
More from UNIVERSITY OF CONNECTICUT
Related pharmaceutical patents in our USPTO index.
-
US 12311017
Identification of immunologically protective neo-epitopes for the treatment of cancers
granted -
US 12251378
Long-acting local anesthetic formulation
granted -
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12060555
MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis
granted -
US 12029787
Method for generating recombinant poxviruses
granted -
US 12018255
Compositions and methods for treating disorders of genomic imprinting
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted
Frequently asked questions
What is US patent 10632072?
US 10632072 (Systems and methods for continuous manufacturing of liposomal drug formulations) is held by UNIVERSITY OF CONNECTICUT. Status: granted. Granted Apr 28, 2020. Expires Apr 23, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10632072?
UNIVERSITY OF CONNECTICUT is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 179 pharmaceutical patents for this assignee.
When does US 10632072 expire?
Our index shows an expiration date of Apr 23, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.